Clinical trial
Risk-Adapted Therapy of Acute Myeloid Leukemia of Adults (18-60 Years) According…
NCT00146120 · University of Ulm, Other · Completed
Key facts
| NCT number | NCT00146120 |
|---|---|
| Title | Risk-Adapted Therapy of Acute Myeloid Leukemia of Adults (18-60 Years) According to the Cytogenetic Result |
| Official title | Risk-Adapted Therapy of Acute Myeloid Leukemia of Adults (18-60 Years) According to the Cytogenetic Result |
| Lead sponsor | University of Ulm, Other |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Acute Myeloid Leukemia |
| Intervention type | Drug |
| Interventions | Idarubicin, Cytosin-Arabinosid, Etoposide, All-trans Retinoid acid |
| Enrollment | 400 |
| Start date | May 1, 1998 |
| Primary completion | May 1, 2005 |
| Completion | May 1, 2005 |
| First posted | Sep 5, 2005 |
| Last update posted | Feb 9, 2009 |
| Countries | Austria, Germany |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: